SCHEDULE: Suvretta Capital Discloses 7.8% Stake in Biohaven Ltd.

Suvretta Capital Management, LLC and affiliated entities reported a 7.8% beneficial ownership stake in Biohaven Ltd. as of December 31, 2025.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen collectively reported beneficial ownership in Biohaven Ltd. Common Shares.
• Suvretta Capital Management, LLC and Aaron Cowen each beneficially own 10,286,937 shares, representing 7.8% of the class.
• Averill Master Fund, Ltd. beneficially owns 8,800,438 shares, representing 6.6% of the class.
• All reported shares are held with shared voting and shared dispositive power by the respective reporting persons.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating a previous disclosure of ownership.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of Biohaven Ltd., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive disclosure. The continued significant stake by a reputable investment firm like Suvretta Capital Management indicates sustained investor confidence, although it is a routine regulatory filing without new operational news.

Positives

• Continued significant institutional ownership by Suvretta Capital Management, LLC and its affiliates, which can signal confidence in Biohaven Ltd.'s long-term prospects.
• The filing explicitly states that the securities are not held for the purpose of changing or influencing control, suggesting a passive investment stance.

Negatives

• No specific negative information is contained within this Schedule 13G filing, as it is a routine disclosure of beneficial ownership.

Risks

• No specific risks related to Biohaven Ltd.'s operations or financial health are disclosed in this beneficial ownership filing.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Biohaven Ltd.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that significant institutional ownership, such as the stake held by Suvretta Capital Management, is common in the biotechnology and pharmaceutical sectors. Such filings provide transparency into major investor positions, which can influence market perception and liquidity. While this filing is a routine disclosure, the continued presence of a prominent investment firm like Suvretta Capital Management in Biohaven Ltd. suggests ongoing interest in the company's potential within the competitive biopharmaceutical landscape.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure, which is a common regulatory requirement for institutional investors acquiring more than 5% of a company's voting class of securities. The reported ownership percentages are typical for significant institutional stakes in publicly traded biotech companies.
• For example, similar filings are routinely observed for other biotech firms like Moderna (MRNA) or BioNTech (BNTX), where large asset managers or hedge funds disclose their positions, often ranging from 5% to 15% of outstanding shares.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing market sentiment and trading activity.
• Management: Awareness of a large, passive institutional holder, which may influence strategic decisions, though the filing disclaims intent to control.

Next Steps

• The reporting persons will file future amendments to this Schedule 13G if their beneficial ownership materially changes (e.g., increases or decreases by more than 1% of the class).

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership and does not contain new operational or financial information that would warrant a change in investment recommendation. The continued significant stake by Suvretta Capital Management suggests ongoing institutional interest, but without further context on Biohaven Ltd.'s performance or strategic developments, a 'hold' recommendation is appropriate for a seasoned investor.

Keywords

Biohaven Ltd., Suvretta Capital Management, Averill Master Fund, Aaron Cowen, Schedule 13G, Beneficial Ownership, Common Shares, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals